Literature DB >> 9370081

Clinical trials of antiangiogenic agents.

P Twardowski1, W J Gradishar.   

Abstract

Acquisition of new blood vessels is a required step in malignant transformation, tumor growth, and metastasis. Inhibition of angiogenesis is one of the most promising new strategies for the treatment of malignant neoplasms. In recent years, several antiangiogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazole, and tecogalan sodium, have entered clinical trials. In this we review, we look at the results of early clinical trials of these agents and discuss the new angiogenesis inhibitors in preclinical development.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9370081     DOI： 10.1097/00001622-199711000-00015

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN： 1040-8746            Impact factor:   3.645


  10 in total

1.  Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.

Authors:  L Guedez; A J McMarlin; D W Kingma; T A Bennett; M Stetler-Stevenson; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest.

Authors:  J R Yeh; R Mohan; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

3.  Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells.

Authors:  J Yatsunami; Y Fukuno; M Nagata; M Tominaga; S Aoki; N Tsuruta; M Kawashima; S Taniguchi; S Hayashi
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

4.  Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay.

Authors:  Liliana Guedez; Alexandra M Rivera; Rita Salloum; Megan L Miller; Jared J Diegmueller; Peter M Bungay; William G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

5.  Effect of nitroxoline on angiogenesis and growth of human bladder cancer.

Authors:  Joong Sup Shim; Yoshiyuki Matsui; Shridhar Bhat; Benjamin A Nacev; Jing Xu; Hyo-eun C Bhang; Surajit Dhara; Kee Chung Han; Curtis R Chong; Martin G Pomper; Alan So; Jun O Liu
Journal:  J Natl Cancer Inst       Date:  2010-11-18       Impact factor: 13.506

6.  Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells.

Authors:  J Yatsunami; N Tsuruta; Y Fukuno; M Kawashima; S Taniguchi; S Hayashi
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

7.  Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin.

Authors:  R S Herbst; A T Lee; H T Tran; J L Abbruzzese
Journal:  Curr Oncol Rep       Date:  2001-03       Impact factor: 5.075

8.  The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase.

Authors:  W T Lowther; D A McMillen; A M Orville; B W Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

9.  Angiogenesis is an independent prognostic factor in malignant mesothelioma.

Authors:  J G Edwards; G Cox; A Andi; J L Jones; R A Walker; D A Waller; K J O'Byrne
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

Review 10.  A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.

Authors:  Michael J Grayling; Munyaradzi Dimairo; Adrian P Mander; Thomas F Jaki
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.